Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196950 | 1.00 | POLB (0.46) | POLBLTA4HKMT2AGHSRYTHDC1 | |
| SCHEMBL6609328 | 0.76 | POLB (0.59) | POLBLTA4HKMT2A | |
| SCHEMBL384446 | 0.75 | HRH3 (0.50) | LTA4HKMT2A | |
| SCHEMBL384444 | 0.74 | SLC6A2 (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL384582 | 0.72 | CYP2D6 (0.33) | POLBLTA4HKMT2AGHSRSLC6A2 | |
| SCHEMBL13705103 | 0.71 | LTA4H (0.56) | LTA4H | |
| SCHEMBL8806149 | 0.70 | POLB (0.58) | POLBLTA4HKMT2A | |
| SCHEMBL8157461 | 0.70 | POLB (0.50) | POLBLTA4HKMT2A | |
| Hydrochloric Acid SCHEMBL4291164 | 0.70 | LTA4H (0.55) | LTA4H | |
| SCHEMBL3373138 | 0.69 | SLC6A2 (0.51) | KMT2AYTHDC1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187479-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2289893-B1 | Haloaryl substituted aminopurines for use in treatment | SIGNAL PHARM LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2112151-B1 | Haloaryl substituted aminopurines for use in treatment | SIGNAL PHARM LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440661-B2 | Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2010186-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8101588-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-7759342-B2 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7723340-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ALBERS RONALD J | 2009-11-05 | — | — | US | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | POLB 2325/4885LTA4H 3792/4885KMT2A 2423/4885 |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | POLB 2178/4885LTA4H 3586/4885KMT2A 2476/4885 |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | POLB 2178/4885LTA4H 3586/4885KMT2A 2476/4885 |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | POLB 2178/4885LTA4H 3586/4885KMT2A 2476/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | POLB 1957/4885LTA4H 3727/4885KMT2A 2560/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | POLB 2178/4885LTA4H 3586/4885KMT2A 2476/4885 |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | TPMT, MGMT, SMAD3 | POLB 2466/4885LTA4H 3840/4885KMT2A 2751/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | POLB 2178/4885LTA4H 3586/4885KMT2A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.